Table 2. CRE-mediated luciferase activity in PHN.

Treatment	% increase over control
DADLE (1 μM)	56 ± 10*
DADLE + BW A1434U	56 ± 2*
DADLE + Nal (10 μM)	–5 ± 3
DADLE + Rp-cAMPS	7 ± 5
DADLE + PTX	0 ± 6
DADLE + QEHA	4 ± 5
Met (2 μM)	46 ± 7*
Met + BW	45 ± 9*
Met + AM281 (10 μM)	–7 ± 8
Met + Rp-cAMPS	3 ± 8
Met + PTX	9 ± 3
Met + QEHA	–4 ± 5
NPA (50 nM)	51 ± 5*
NPA + BW	48 ± 3*
NPA + Spip (10 μM)	5 ± 3
NPA + Rp-cAMPS	–3 ± 5
NPA + PTX	–1 ± 5
NPA + QEHA	5 ± 7
EtOH (100 mM)	41 ± 9*
EtOH + BW (10 μM)	–7 ± 2
EtOH + Rp-cAMPS (20 μM)	–5 ± 5
EtOH + PTX (50 ng/ml)	4 ± 5
EtOH + QEHA	–4 ± 6
Carb (10 μM)	10 ± 5
UK (10 μM)	11 ± 8
Forskolin (10 μM)	78 ± 7*

^*P < 0.01 compared with control as in Table 1